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CELAB is not just an Acronym. It represents the Center for Ethics and Law in Bio-
medicine in Budapest and it embraces manifold activities conducted by lawyers, 
philosophers, anthropologists, ethicists and other social scientists in the Center. In 
2005 the idea behind establishing CELAB was related to the recognition of a new 
and increasingly developing interdisciplinary fi eld: the ethical, legal, and social im-
plications of biotechnological advances. Life sciences, especially biomedicine, tradi-
tionally focused on the restoration of health and ‘normality’. However, entering the 
age of the human genome project, biobanks, stem cell research, and nanotechnolo-
gy the role of biomedical science has shifted toward the purposeful transformation 
of various human capacities. For instance, while the new reproductive technologies 
could overcome some problems of infertility, they also pose new questions of what 
sexuality, gender, and kinship mean in our contemporary societies. We also have to 
realize that the technologies of genetic testing and preimplantation diagnosis allow 
for enhancement. And all these changes force the various social sciences and the 
practice of governance to rethink decision-making in science policy, the way re-
sources are allocated, and the ethical and legal concerns related to the various uses of 
genetic data. Our Center has focused on these issues in the framework of diff erent 
European research projects funded by the European Union, European Science 
Foundation and by UNESCO.
Our fi rst year of operation (the 2005-2006 academic year) was dedicated to setting 
priorities, developing networks and creating a biomedical-legal database. In the sec-
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ond year we submitted numerous applications to various research grants, and within 
a short time we started two new research projects. During our third year of research 
activities, the network of CELAB partners, associates and collaborators have become 
truly international, which is accentuated by our participation in fi ve European re-
search projects. Our small research team has been consequently expanded, and to-
gether with our new colleagues and research associates, we are working on a wide 
range of academic and administrative tasks. Regardless of this necessary institutional 
expansion, our staff  has been able to preserve its original enthusiasm to work in the 
exciting cross-disciplinary domain of biomedical law and ethics. 
CELAB works on the national, regional, and international levels. In European re-
search consortia knowledge about the Hungarian and Central European legal sys-
tem is often required while it is also essential to be familiar with other European le-
gal and ethical approaches. Nevertheless, as international research projects have 
become increasingly global in their scope, we have also developed a wider compara-
tive perspective in our work that includes studies of North American and East Asian 
legal and ethical discourses.
Moreover, we seek to integrate the results of these research projects into our aca-
demic teaching curricula. Th erefore, we have organized workshops and seminars, 
fi lm screenings and policy debates that are open to the CEU community and be-
yond. We also participate in legal policy development activities and provide research 
tools for the international scientifi c community. For instance, in 2007 we launched 
the new version of the Biolaw Database that makes it possible for researchers and 
students to study legal instruments and ethical norms in the fi eld of biomedicine 
and biotechnology more systematically, or just to learn about the possible directions 
of future comparative research. In addition, we update our CELAB website on a 
daily basis. 
At the beginning of 2008 we received a UNESCO grant. Within less than a year we 
completed a very ambitious project: the promotion of implementing the three bio-
ethics-related Declarations of UNESCO in fi ve countries – Croatia, the Czech Re-
public, Italy, Hungary, and Serbia. Th is project required legal policy work but it also 
gave us an opportunity to develop and reaffi  rm further professional contacts in the 
region with similar centers and scholars. As a result, CELAB published a series of 
booklets in fi ve languages and organized a workshop with lectures and panels to dis-
cuss the possible methods to implement these instruments in teaching and to infl u-
ence national legislation in the fi eld of bioethics and related human rights. Although 
the working language of CELAB is English, this UNESCO funded project gave us 
the opportunity to learn about diff erent cultural approaches to working in the fi eld 
of bioethics and human rights.
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Since 2007 we have also participated in the Francophone network of biomedical 
lawyers. Th is network, which has been expanded since its establishment, currently 
works on several thematic issues of bioethics and biomedical law and in each inter-
disciplinary workshop panel the participants seek to explore and understand the 
cultural diff erences behind the formulation of various bio-legal norms. Th e fi rst 
workshop in Rennes, organized by Professor Brigitte Feuillet-Liger, was a big success 
and the fi rst publication of the network on Assisted Reproduction and Anonymity 
has been already published. Th e next workshop of the network was held in Kyoto in 
2009 and focused on the bioethical problems in the fi eld of health care provided to 
adolescents. Th e third theme will elaborate the ethical issues of the death and dying 
with the family. 
Th e EU project that is perhaps in the most advanced stage is called PRIVILEGED 
(Privacy in Law, Ethics and Genetic Data). Th e aims of this project were to make 
recommendations for research practice and public policy-making, including regula-
tory options at the national, regional, and European levels. PRIVILEGED has 
sought to identify, analyze and compare plural ethical, cultural, and social concepts 
of legitimate privacy interest engaged by research using genetic databases and bio-
banks. It articulates the relation between such concepts and the current regulation 
of research using genetic data and biobanks. PRIVILEGED focuses on the various 
privacy interests, particularly grounded within intimate and familial relationships in 
various research areas, especially in the so-called biobanking applications. Th is is a 
mega-project in which representatives of no less than thirty-two universities partici-
pate, among them not only European experts but also lawyers from Japan, Taiwan 
and Israel. As part of the project, two major reports have already been submitted. 
Th e second project focuses on the governance of the so called gene-banks and the 
European legal and ethical framework to regulate their activities (Acronym: Gene-
BanC). Our team focuses mainly on the cases of countries that joined the European 
Union in 2004, most of which have not adopted legislation or guidelines in the fi eld 
of classical biobanks, or have done so relatively recently without extensive experi-
ence. 
In 2008 we started our third research project in this fi eld, TISS.EU, mobilizing the 
resources of ten universities in Europe. Th e major aim of this project is to carry out 
a high-quality interdisciplinary comparative analysis of European health policies in 
order to assess the impact of EU legislation and to explore the relevant ethical and 
legal situation across the European Union. Th e fi rst TISS.EU project meeting was 
held in Göttingen, Germany and focused on the ethical and legal challenges to con-




Another EU funded project, NANOPLAT (Framing the Deliberative Process on the 
Responsible Development of Nanoscieneces and Nanotechnologies) also started in 
2008, focusing on ‘deliberative processes’ in nanotechnology because these may be 
seen as useful, although possibly highly problematic regulatory forms supplement-
ing democratic mechanisms. On the other hand, the conceptual shift from ‘govern-
ment’ to ‘governance’ might allow for more participatory forms of shaping public 
policy. 
Th e fi fth EU funded research project we participate in is RemediE (Regenerative 
Medicine in Europe: Emerging Needs and Challenges in a Global Context). Th is 
project focuses on the present and future role of regenerative medicine in the health 
care industry, especially on the relevant intellectual property rights and patent is-
sues. Th erefore, the contributors to this project will explore and analyze interna-
tional and regional policies regarding the patentability of living organisms, human 
genes and stem cells, as these are highly critical areas of research where market inter-
ests and ethical concerns frequently collide. 
Th e academic year of 2008–2009 was a very intensive period for the Center for Eth-
ics and Law in Biomedicine (CELAB). We participated, simultaneously, in fi ve Eu-
ropean Commission funded research projects (GeneBanC, NANOPLAT, Privi-
leged, RemediE and the TissEu), and contributed to three more EU projects as 
consultants. In addition to working on these European programs, CELAB also 
completed a UNESCO fi nanced project on the implementation of the three bioeth-
ics declarations in fi ve countries of the wider Central European region (Croatia, 
Czech Republic, Hungary, Italy, and Serbia). 
Among the EU sponsored research projects, perhaps one of the biggest achieve-
ments was to complete and publish a comparative survey of the available legal regu-
lations of biobanks in eleven European Union member states (Cyprus, Czech Re-
public, Estonia, Greece, Hungary, Italy, Latvia, Lithuania, Malta, Poland and 
Romania). Research within the GeneBanC project required the application of inter-
disciplinary methods: collection of data through desk research, compiling and ad-
ministering detailed questionnaires, conducting fi eldwork and interviewing relevant 
experts in the region.
In addition to the fi elds in which we had conducted research before, we have devel-
oped expertise in some new research areas, such as the social-ethical aspects of nano-
technology and the intellectual property aspects of regenerative medicine.
Participation in the NANOPLAT project prompted us to accumulate knowledge on 
the recent advances in nanotechnology, even outside of our traditional research in-
terest in the ethics and law of life sciences. Th is short but very intense project fo-
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cused on the deliberative processes in shaping the contours of policies in the fi eld of 
nanotechnologies. 
In 2008 we started to work on another new topic within the framework of the 
RemediE project, which lies at the intersection of ethics and biotechnology. Th e 
emergence of biotechnology and the extension of the scope of patent rights have by 
now become a public concern. From genes through genetically modifi ed plants and 
animals to human cells, each stage of accretion of patentability in this arena has 
been contested. Much of this opposition arises from cultural concerns about the 
moral appropriateness of property rights being applied to living, especially to hu-
man-derived cells. Because of these ethical controversies, this EU funded research 
project gives us an opportunity to understand the process in which biotechnological 
research becomes increasingly commercialized and lucrative new markets for tech-
nological advances are created.
Th e workshop CELAB organized in the framework of the TissEu Project was a suc-
cessful event as the international experts invited analyzed a new and often misinter-
preted perspective on biobanking: the questions of tissue anonymization. 
During the last academic year, we also participated as consultants in several other 
EU projects, namely From GMP to GBP (From GMP to GBP: Fostering Good Bio-
ethical Practices (GBP) in the European Biotech Industry), NMD–Chip (Develop-
ment of Targeted DNA Chips for High Th roughput Diagnosis for Neuromuscular 
Disorders) and BBMRI (Biobanking and Biomedical Resources Infrastructure).
I am very grateful to be able to work in such an inspiring fi eld and with motivated 
colleagues. 
